Dexmedetomidine 01 — Competitive Intelligence Brief

Dexmedetomidine 01 (Dexmedetomidine 01) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic receptor agonist. Area: Anesthesia and Sedation.

marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor Anesthesia and Sedation Small molecule

Target snapshot

Dexmedetomidine 01 (Dexmedetomidine 01) — Guangzhou General Hospital of Guangzhou Military Command. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexmedetomidine 01 TARGET	Dexmedetomidine 01	Guangzhou General Hospital of Guangzhou Military Command	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Clonidine Pill	Clonidine Pill	Weill Medical College of Cornell University	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Dexmedetomidine 0.5 microgram/kg	Dexmedetomidine 0.5 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Clonidine Oral Liquid Product	Clonidine Oral Liquid Product	Region Örebro County	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Intravenous dexmedetomidine	Intravenous dexmedetomidine	University of Jordan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Preemptive Analgesia Of Dexmedetomidine	Preemptive Analgesia Of Dexmedetomidine	China International Neuroscience Institution	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic receptor agonist class)

1. Allergan · 3 drugs in this class
2. Eye & ENT Hospital of Fudan University · 2 drugs in this class
3. National Cancer Institute, Egypt · 2 drugs in this class
4. The University of Hong Kong · 2 drugs in this class
5. Sindh Institute of Urology and Transplantation · 2 drugs in this class
6. Fayoum University Hospital · 1 drug in this class
7. First Affiliated Hospital of Chongqing Medical University · 1 drug in this class
8. Guangzhou General Hospital of Guangzhou Military Command · 1 drug in this class
9. Icahn School of Medicine at Mount Sinai · 1 drug in this class
10. KAT General Hospital · 1 drug in this class